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A B S T R A C T
The development of mucoadhesive in situ gelling formulations for intravesical application may improve the
therapeutic outcomes of bladder cancer patients. In this work, chitosan/β-glycerophosphate (CHIGP) thermo-
sensitive formulations have been prepared using three diﬀerent chitosan grades (62, 124 and 370 kDa). Their
ability to form in situ gelling systems triggered by changes in temperature upon administration to urinary bladder
were evaluated using vial inversion and rheological methods. Texture analysis was used to study their mu-
coadhesive properties as well as syringeability through the urethral catheter. The retention of CHIGP for-
mulations, with ﬂuorescein sodium as the model drug, was studied on porcine urinary bladder mucosa ex vivo
using the ﬂow-through technique and ﬂuorescent microscopy. CHIGP formulations containing mitomycin-C
were prepared and drug release was studied using in vitro dialysis method. It was established that the molecular
weight of chitosan inﬂuenced the thermogelling, mucoadhesive and drug release behaviour of the in situ gelling
delivery systems. Formulations prepared from chitosan with greatest molecular weight (370 kDa) were found to
be the most promising for intravesical application due to their superior gelling properties and in vitro retention in
the bladder.
1. Introduction
Bladder cancer has been identiﬁed as a major clinical issue with
prevalence and mortality rate escalating globally (Torre et al., 2015)
and there is an increasing number of research in this area to improve
drug delivery (Hu et al., 2018; Kolawole et al., 2017). Oral and other
systemic routes of administration are not employed for bladder cancer
treatment, especially at the early stages of the disease because ther-
apeutic drug concentrations cannot be achieved in the bladder due to
the hostile environment of the stomach, hepatic metabolism as well as
drug transport to non-target organs (GuhaSarkar and Banerjee, 2010).
Consequently, drugs are instilled via the catheter directly into the
bladder, referred to as intravesical drug delivery, to increase local drug
availability. Local route of administration has been explored further for
bladder cancer treatment because it minimises systemic toxicity and
facilitates targeted drug delivery to urothelial malignant tissues
(GuhaSarkar and Banerjee, 2010; Kolawole et al., 2017).
Polymers exhibiting the ability to adhere to mucosal tissues in the
bladder are typically referred as mucoadhesive. The mucoadhesive
dosage forms are commonly prepared using polymers that interact with
glycoprotein components of mucin through non-covalent bonding like
hydrogen bonds, chain entanglements and electrostatic interactions
(Khutoryanskiy, 2011; Davidovich-Pinhas and Bianco-Peled, 2014;
Khutoryanskiy, 2014). They are particularly desirable for drug delivery
to the bladder because they may be able to overcome some inherent
limitations of intravesical administration such as substantial drug di-
lution and wash-out during urine formation and elimination.
Chitosan, (1,4)-2-amino-2-deoxy-β-D-glucan, is a natural polymer
generated by the partial deacetylation of chitin under basic or enzy-
matic conditions (Ravi Kumar, 2000). It is commercially available as
various grades depending on molecular weight and degree of deacety-
lation, with the highly deacetylated forms preferred because they can
be readily functionalised for a variety of biomedical applications
(Jayakumar et al., 2010). The continued interest in chitosan over the
last two decades for drug delivery and tissue engineering is due to its
biocompatible, biodegradable, mucoadhesive, and cell permeation
properties (Bernkop-Schnürch and Dünnhaupt, 2012; Jayakumar et al.,
2010). Tyagi et al reported that chitosan exhibited properties desirable
for the formulation of intravesical dosage forms: eﬀective and extended
mucoadhesion as well as non-interference with bladder physiology
(Tyagi et al., 2006).
Glycerophosphate is presented as its sodium salt which is
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hydrolysed in the body to inorganic phosphate and glycerol (U.S.
National Library of Medicine, 2005). It has been approved by MHRA as
a phosphate supplement in intravenous nutrition for adult patients
marketed by Fresenius Kabi, which is a concentrate containing 21.6%
sodium glycerophosphate for infusion (MHRA, 2016). The possibility of
chitosan forming in situ gelling systems with physical cross-linking was
ﬁrst reported by Chenite et al. (2000), where chitosan solution
(pH∼ 6) formed a gel in the presence of β-glycerophosphate at about
37 °C. Chitosan/β-glycerophosphate mixtures were reported to be safe,
biodegradable and thermosensitive with relatively easy drug loading
that allow its release at the point of administration; plus their pre-
paration does not require expensive equipment (Hastings et al., 2012;
Kean and Thanou, 2010). They also display sustained gel stability for
90 days when stored at −80 °C (Peng et al., 2013).
Various researchers investigated one or two grades of chitosan or its
derivatives with αβ- or β-glycerophosphate and reported improved ef-
ﬁcacy and sustained drug release of various therapeutics (Abdel-Bar
et al., 2014; Aliaghaie et al., 2012; Khodaverdi et al., 2012; Kim et al.,
2010; Peng et al., 2013; Supper et al., 2013; Zheng et al., 2010; Zhou
et al., 2015). Zhang and co-workers have mixed Bacillus Calmette
Guérin (BCG) with ferric oxide (Fe3O4) nanoparticles and incorporated
the nanoparticulate formulation into chitosan/β-glycerophosphate in
situ gelling systems to generate composite system for intravesical
bladder cancer treatment (Zhang et al., 2013). To the best of our
knowledge, chitosan/β-glycerophosphate in situ gelling systems have
not been explored for intravesical drug delivery. Moreover, the wash-
out inﬂuence of artiﬁcial urine on the retention of in situ gelling drug
carriers has not been studied. The drug-loaded in situ gelling formula-
tions may form a mucoadhesive gel layer across a wide surface area of
the bladder mucosa allowing for therapeutic concentrations of the drug
to diﬀuse across urothelial cancerous tissues for extended period of
time.
Mitomycin-C is the drug used for superﬁcial/non-invasive bladder
cancer therapy, administered preferably immediately or ≤24 h after
transurethral resection of bladder tumor to reduce recurrence rate
(Mostaﬁd et al., 2006; NICE, 2015). Mitomycin-C is generally ad-
ministered at a concentration of 1–2mg/mL for superﬁcial bladder
cancer treatment (Kirin, 1992). According to a randomised controlled
trial, 1 mg/mL mitomycin-C formulation (20–40mL) resulted in re-
currence reduction of 23.5% in bladder cancer patients (Au et al.,
2001). So, mitomycin-C at 1mg/mL was selected for the current study.
Bilensoy and co-workers explored cationic chitosan- and poly-L-ly-
sine-coated poly-Ɛ-caprolactone (PCL) nanoparticles for improved in-
travesical delivery of mitomycin-C (Bilensoy et al., 2009; Erdoğar et al.,
2014, 2012). They reported that chitosan-coated PCL nanoparticles
used to treat bladder tumour in rats in vivo displayed superior anti-
tumour eﬃcacy (evident with more rats alive up to 83 days) relative to
other groups treated with poly-L-lysine-coated PCL nanoparticles and
uncoated chitosan nanoparticles (Erdoğar et al., 2014). Their ﬁndings
suggested that chitosan coated drug carriers may be eﬃcient for im-
proved drug localisation and accumulation in bladder tissues.
Despite the potential of in situ gelling systems to facilitate controlled
drug release (Packhaeuser et al., 2004), they have not been explored as
delivery systems for mitomycin-C in enhancing the therapeutic out-
come of bladder cancer. This current work sought to explore chitosan-
based in situ gelling systems to improve the residence time of mito-
mycin-C in the bladder. We present the ﬁrst report on the formulation
of chitosan/β-glycerophosphate gels using three grades of chitosan for
intravesical drug delivery, with chitosan molecular weight modulating
gelation, mucoadhesive and drug release proﬁle of the CHIGP for-
mulations.
2. Materials and methods
2.1. Materials
Low (LCHI), medium (MCHI) and high molecular weight (HCHI)
grades of chitosan, β-glycerophosphate (β-GP), FITC-dextran (3–5 kDa),
dextran (5 kDa), ﬂuorescein sodium, triﬂuoroacetic acid, urea, uric
acid, magnesium sulphate heptahydrate, sodium hydrogen phosphate,
creatinine, sodium bicarbonate, sodium sulphate, disodium oxalate and
trisodium citrate acid were purchased from Sigma-Aldrich (UK); dis-
odium phosphate, sodium chloride, potassium chloride, ammonium
chloride, and calcium chloride dihydrate, mitomycin-C, HPLC grade
methanol, acetonitrile and water and other chemical reagents were
from Fischer Scientiﬁc (UK) and used as received without further pur-
iﬁcation. Dialysis membranes with molecular weight cut oﬀ 12–14 kDa
were supplied by Medicell International (UK). Freshly excised porcine
urinary bladders were provided by PC Turner Abattoir (Farnborough,
Hampshire, UK).
2.2. Characterisation of chitosan
The molecular weights of the three grades of chitosan were de-
termined by gel permeation chromatography using 0.1M sodium ni-
trate as a solvent system (pH 2.1) with a ﬂow rate of 1mL/min at 25 °C.
Approximately 20mg of LCHI, MCHI and HCHI were dissolved in 3mL
deuterium oxide (D2O) acidiﬁed with 30 µL triﬂuoroacetic acid for 12 h
at room temperature and the 1H NMR spectra were recorded using
400MHz ULTRASHIELD PLUS™ B-ACS 60 spectrometer (Bruker, UK).
The degrees of acetylation of chitosan samples were evaluated based on
the integration pattern of the N-acetyl protons (δ=1.6 ppm) relative to
the other protons (δ=3.0–3.6 ppm). An exemplar 1H NMR spectrum is
provided in Fig. S1 (Supplementary information).
The acetylation level was evaluated using the following equation
(Sogias et al., 2008):
= ×−DA(%) (I 3) (I 6) 100%CH3 H2 H6 (1)
where the integral intensity of N-acetyl protons is denoted as I CH3 and I
H2-H6 depicted the integral intensities of H-2, -3, -4, -5 and H-6 of the
deacetylated glucosamine ring of chitosan.
2.3. Preparation of CHI and CHIGP formulations
1% w/v LCHI in 12% w/v β-GP (LCHIGP), 1% w/v MCHI in 12% w/
v β-GP (MCHIGP) and 1% w/v HCHI in 12% w/v β-GP (HCHIGP) for-
mulations were prepared according to a previously reported procedure
with modiﬁcation (Khodaverdi et al., 2012). Brieﬂy, 1% w/v of chit-
osan solutions were prepared in 0.1M acetic acid (buﬀered to pH 4
using 1M potassium hydroxide) for 12 h at room temperature. The β-
GP solutions (48% w/v, 2mL) were added to chitosan solutions (6 mL)
in a dropwise manner under ice-cold conditions, giving a ﬁnal β-GP
concentration of 12% w/v and chitosan to β-GP volume ratio of 3:1.
Chitosan solutions were also prepared without β-GP for comparison.
2.4. Characterisation of CHIGP formulations
2.4.1. pH determination
The pH of CHIGP solutions was measured using a pH meter
(SevenEasy Mettler-Toledo). Data was expressed as mean ± S.D
(n= 3).
2.4.2. Zeta potential measurements
The zeta potential of the formulations was evaluated based on our
previously reported method (Kolawole et al., 2018). Brieﬂy, folded
DTS-1070 capillary cells (Malvern, UK) were ﬁlled with 1% w/v chit-
osan solutions or CHIGP formulations (sol form) and their zeta-poten-
tial values were determined at 25 and 37 °C using Zetasizer Nano-ZS
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(Malvern Instruments, UK). The samples were studied after 1 in 20
dilution to 0.05% w/v chitosan: 0.6% w/v β-glycerophosphate using
ultrapure water. The instrument was set to operate at an absorbance of
0.01 and refractive index of 1.59. Measurements were conducted in
triplicates with 50 sub-runs per reading.
2.4.3. Syringeability through the catheter
The ability of various formulations to pass through a catheter via a
syringe was evaluated using TA-XT Plus Texture Analyser (Stable Micro
Systems, UK) operated at a compression mode. Male SpeediCath®
28,414 CH 14/4.7 mm catheter (Coloplast A/S, Denmark) was used in
this study. The experiment was carried out using a previously reported
method with slight modiﬁcation (Jones et al., 2000). Brieﬂy, the sam-
ples were loaded into 2mL plastic syringes connected to a catheter. The
syringe was vertically secured while the probe was lowered until it had
an initial contact with the syringe plunger. Then, the probe was lowered
at a constant speed of 2mm/s for 25mm (Fig. S2, Supplementary in-
formation). The work done to expel the syringe contents (work of
compression) at 25 °C was assessed as a function of the area under the
force-distance curve recorded during the plunger compression (n=3).
Sodium chloride (0.9% w/v), which is typically used in the urology
clinic to prepare mitomycin-C solutions for intravesical administration,
served as the control.
2.4.4. Gelation studies using vial inversion method
The gelation time of the formulations was evaluated at 37 °C using a
modiﬁed version of a vial inversion method reported earlier
(Khodaverdi et al., 2012). Brieﬂy, 3mL LCHIGP, MCHIGP, HCHIGP
samples were incubated in glass vials in a temperature-controlled water
bath (Grant Instruments, Ltd, Cambridge) at 37 °C. The vials were in-
verted at predetermined time intervals to evaluate the ﬂow of the
samples by visual examination. The gelation time was identiﬁed as the
point where the formulations stopped ﬂowing.
2.4.5. Rheology
The viscoelastic properties of the formulations were evaluated using
an AR-2000ex rheometer (TA Instruments, UK) operated at the oscil-
latory mode using 40mm parallel plate and a trim gap of 0.4mm. The
samples were steadily deposited onto the lower plate of the rheometer
and the chosen trim gap was applied to reduce sample shearing, with
the solvent trap in place during sample analysis to prevent sample loss.
In order to determine the linear viscoelastic region of the samples at
25 °C, a “strain sweep” was carried out, where the magnitude of strain
applied on the samples was steadily increased from 0.05 to 10%, at a
constant frequency of 1 Hz. The strain, where the storage/elastic
modulus (G′) and loss/viscous modulus (G″) was unchanged and in-
dependent of the prevalent frequency, was chosen for the frequency
sweep studies.
2.4.5.1. Gel strength determination: Frequency sweep analysis. Based on
the strain sweep analysis, 1% strain was chosen for the “frequency
sweep” conducted at 25 °C with samples scanned from frequency of
0.01–10 Hz to conﬁrm optimal frequency for the rheological
experiment. In order to evaluate the gel strength of the formulations,
a “frequency sweep” was carried out at 37 °C over the frequency range
of 0.01–10 Hz, applying 1% strain. The gel strength of the samples was
evaluated based on the ratio of their storage modulus (G′) to loss
modulus (G″) at a frequency of 0.1 Hz. The higher the G′/G″ value, the
stronger the gel and vice versa (Ström et al., 2014).
2.4.5.2. Gelation temperature determination: Temperature ramp test. The
gelation temperature of the samples was evaluated using a temperature
ramp test with samples heated from 20 to 50 °C at 1 °C/min, frequency
and strain of 1 Hz and 1%, respectively. The sol-gel transition
temperature was the temperature, where a rapid increase in the
magnitude of G′ relative to G″ as the samples are subjected to
increasing temperature via the rheometer plate. The tangent of the
loss modulus to storage modulus (tanδ) was also evaluated over the
studied temperature range. LCHIGP, MCHIGP and HCHIGP samples
were also evaluated for their storage modulus values at 37 °C during
temperature ramp test as this rheological parameter depicted their
elastic properties at physiological temperature which impacts their
gelation potential.
2.4.5.3. Gelation time determination: Time sweep analysis. The gelation
time was evaluated by carrying out a time sweep experiment, with
samples maintained at 37 °C for 30min, applying a respective strain
and frequency of 1% and 1 Hz. The gelation time is identiﬁed as the
time, where there is a sharp increase in the G′ value relative to that of
G″, when samples are maintained at 37 °C for predetermined length of
time. The tangent of the ratio of the loss modulus to storage modulus
(tanδ) over 30min was also investigated. As some samples displayed
similar gelation time during time sweep analysis but diﬀerent gelation
times recorded during the vial inversion method, the G′ values of the
CHIGP systems (which correlates with their elastic properties) after
30min of maintaining them at 37 °C were also evaluated.
2.5. Retention on porcine bladder: Urine wash-out experiment
The artiﬁcial urine used for ex vivo porcine retention and drug re-
lease studies was prepared according to a previously reported method
(Chutipongtanate and Thongboonkerd, 2010). Brieﬂy, the following
compounds were dissolved in 2 L ultrapure water (18.2MΩ): urea
(24.27 g), uric acid (0.34 g), magnesium sulphate heptahydrate
(1.00 g), sodium hydrogen phosphate (1.00 g), disodium phosphate
(0.11 g), creatinine (0.90 g), sodium bicarbonate (0.34 g), sodium sul-
phate (2.58 g), disodium oxalate (0.03 g), trisodium citrate (2.97 g),
sodium chloride (6.34 g), potassium chloride (4.50 g), ammonium
chloride (1.61 g), and calcium chloride dihydrate (0.89 g). The re-
sultant artiﬁcial urine had a ﬁnal pH of 6.2 ± 0.2.
The mucosal retention of ﬂuorescein sodium on porcine urinary
bladder mucosa, in the presence of chitosan and CHIGP samples was
investigated using ﬂuorescent MZ10F microscope (Leica Microsystems,
UK) coupled with an “ET GFP” ﬁlter and a Zeiss Imager with exposure
time of 70ms (A1/AxioCam MRm, 1296×966 pixels; 0.8×magniﬁ-
cation), according to a method earlier developed by our group (Mun
et al., 2016) with slight modiﬁcation. To ensure that the mucus layer
was preserved on the bladder tissue, the study was carried out using
freshly excised porcine urinary bladders stored on ice during transport
from the abattoir to the laboratory, refrigerated (4 °C) and used within
24 h. Contact with the mucosal side of the bladder tissue was avoided
during excision of the required bladder sections (about 1.5×2.5 cm)
and rinsed with artiﬁcial urine solution (∼3mL) prior to tissue ima-
ging. The bladder tissue was placed on a 75mm×25mm glass slide
and maintained in an incubator at 37 °C during urine wash-out (Fig. S3,
Supplementary information). Microscopic images were recorded on
each tissue sections before and after applying∼50 µL of sample as well
as after each of the ﬁve washing cycles with 10mL artiﬁcial urine/cycle
at 2mL/min. Image J software (Java 8, National Institute of Health,
USA) was employed to evaluate the microscopic images, generating
mean ﬂuorescence values as a function of urine volume used for the
wash-out. The normalised ﬂuorescence intensity during each urine
wash-out cycle is obtained by subtracting the background ﬂuorescence
intensity from the raw ﬂuorescence intensity at the wash-out cycle of
interest. The value “1” was used to depict the ﬂuorescence intensity
from the tissue before artiﬁcial urine wash-out. The WO50 values were
determined using the polynomial ﬁt of the wash-out graphs (Fig. S4,
Supplementary information), which represents the volume of artiﬁcial
urine needed to wash out 50% of the formulations.
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2.6. Mucoadhesive properties of the formulations
The TA-XT Plus Texture Analyser (Stable Micro Systems Ltd, UK)
coupled with a 5 kg load cell was used as an additional technique to
study the mucoadhesive properties of the formulations. Chitosan solu-
tion (0.4% w/v) served as the positive control, while the negative
control was dextran solution (0.4% w/v). Porcine bladder tissues were
secured at the base of a cylindrical container. The bottom of the cy-
lindrical container had a circular cut-out region (20mm in diameter)
exposing the mucosal surface of the bladder tissue. This container was
screwed onto the probe of the texture analyser through a hole drilled on
the lid of the container. Another bladder tissue was placed on a petri
dish and coupled onto the lower platform of the texture analyser, ex-
posing bladder mucosal surface (20mm in diameter) as shown in Fig.
S5. The tests were performed using an earlier reported equipment set-
tings (Caló et al., 2016) with slight modiﬁcation: pre-speed test
1.0 mm/s; test speed 0.1mm/s; post-test speed 0.1mm/s; applied force
0.05 N; contact time 120 s; trigger type auto; trigger force 0.1 N; and
return distance of 10.0 mm. Bladder tissues were incubated at 37 °C for
5min prior to the study and the samples (0.4 mL) were applied onto the
exposed area of the bladder tissue secured onto the lower platform of
the texture analyser. The probe was then lowered such that the blank
tissue comes in contact with the formulation applied onto the tissue
secured on the lower platform for 2min after which the parameters of
interest (detachment force and total work of adhesion) were de-
termined as shown in Fig. S6 (Supplementary information). The Texture
Analyser software (T.A. Exponent, Stable Micro Systems, UK) was used
to record the force versus distance curves. The maximum force needed
to detach tissue from formulation indicated the adhesive strength of the
samples, while the total work of adhesion was evaluated from the area
under the force versus distance curve (Boateng et al., 2013; Caló et al.,
2016).
2.7. Mitomycin-C in vitro release experiment
2.7.1. Preparation of mitomycin-C loaded CHIGP formulations
Mitomycin-C-loaded CHIGP formulations were prepared by dissol-
ving 2mg mitomycin-C in 1 %w/v chitosan solutions (1.5 mL) and
vortexed for one minute before β-GP solution (48% w/v) was added
dropwise under ice-cold conditions and stirred for a further 30min,
producing a ﬁnal β-glycerophosphate concentration of 12% w/v (giving
MMC/LCHIGP, MMC/MCHIGP, MMC/HCHIGP). Mitomycin-C-loaded
LCHI, MCHI and HCHI samples were prepared without addition of β-
GP. This method was used because earlier studies reported that drug
containing formulations exhibit superior sustained release proﬁle re-
lative to formulations, where drug was incorporated into the CHIGP
mixture (Abdel-Bar et al., 2014; Zhou et al., 2008).
2.7.2. Mitomycin-C in vitro release eﬃciency
In vitro drug release studies were carried out using a modiﬁed
method used by Senyiğit et al. (2015). Brieﬂy, 2mL mitomycin-C
loaded CHI and CHIGP solutions were placed in dialysis membrane bags
(12–14 kDa MWCO) and allowed to gel in a water bath at 37 °C for 1 h.
The dialysis bags with the gelled samples were placed in a stoppered
100mL glass bottle containing 40mL of artiﬁcial urine (pH 6.2 ± 0.2),
maintained in a shaker water bath at 37 °C (60 rpm). At predetermined
time intervals (0, 0.5, 1, 2, 4, 6, and 24 h), 1 mL of artiﬁcial urine was
taken and replenished with same amount of fresh artiﬁcial urine. Drug
content was analysed using previously reported HPLC-UV method with
slight modiﬁcation (Myers et al., 2017). The HPLC instrument was
coupled with the quaternary pump and VWD UV detector (Agilent,
Germany) operated at 365 nm. The aliquot samples (10 µL) were in-
jected into the reverse phase C18 column, 150mm×4.6mm, 5 µM
(Dionex™, Thermo Scientiﬁc, UK) maintained at 25 °C. The mobile
phase consisted of 83.5% of 25mM sodium phosphate (pH 5.4) and
16.5% of methanol/acetonitrile (1:1), which was run in an isocratic
mode at a ﬂow rate of 1.5 mL/min, with run time of 15min. Mitomycin-
C eluted at ≈10min, depicted on a typical chromatogram, Fig. S7
(Supplementary information). The standard curve of mitomycin-C was
generated by analysing eight standard solutions of known concentra-
tions.
2.8. Statistical analysis
All studies were carried out in triplicates, data expressed as
mean ± SD and statistical diﬀerences were determined using t-test and
One-Way ANOVA/post-hoc Bonferroni test with GraphPad Prism (ver-
sion 5.04, USA) with p < 0.05 implying statistical signiﬁcance.
3. Results and discussion
3.1. Characterisation of chitosan and chitosan/β-glycerophosphate
formulations
According to the gel permeation chromatography data, the low
(LCHI), medium (MCHI) and high (HCHI) molecular weight chitosan
grades were 62, 124 and 370 kDa, with polydispersity indices (PDI) of
3.43, 3.54 and 6.98, respectively. The degrees of deacetylation were
82 ± 1%, 72 ± 2%, and 71 ± 2%, respectively, which are in good
agreement with those used by previous researchers to formulate CHIGP
in situ gelling systems (Supper et al., 2014; Zhou et al., 2015).
The focus of this study was to develop and characterise thermo-
responsive and mucoadhesive formulations using chitosan/β-glycer-
ophosphate mixtures. LCHIGP, MCHIGP and HCHIGP were formulated
to contain 1% w/v chitosan, 12% w/v β-glycerophosphate and chitosan
to β-glycerophosphate volume ratio of 3:1. All these formulations
formed transparent solutions (pH 7.1–7.3) below 37 °C and turned into
cloudy gels at 37 °C (Fig. 1). Chitosan/β-glycerophosphate mixtures are
transparent below physiological temperature due to electrostatic at-
traction between negatively charged phosphate groups of β-glycer-
ophosphate and positively charged ammonium groups of chitosan as
well as hydrogen bonding involving chitosan functional groups
(Chenite et al., 2001). Alcohol groups of glycerophosphate provide
additional hydration due to hydrogen bonding with water molecules,
thereby preventing gel formation below physiological temperature
(Ruel-Gariépy et al., 2000). An increase in temperature up to 37 °C
results in partial dissociation of hydrogen bonds with water molecules,
leading to the formation of less hydrated gel.
All chitosan/β-glycerophosphate mixtures showed fast in situ gela-
tion as detected using vial inversion method. MCHIGP and HCHIGP
formulations formed physical gel within 7 ± 2min and 5 ± 1min,
respectively, while LCHIGP mixture formed very weak gel at
15 ± 5min that eventually collapsed upon further incubation at 37 °C
(Fig. 1).
Despite the fact that LCHI had the greatest extent of deacetylation
and a favourable pH of 7.4 ± 0.2 (Table 1), its gelation was not sus-
tained. One of the reasons for this behaviour is the reduced degree of
entanglements in LCHIGP, resulting in lower viscosity at increased
temperature (Aliaghaie et al., 2012). This ﬁnding is in contrast with the
study by Khodaverdi et al. (2012), who reported fast onset of gelation
with highly deacetylated chitosan as a result of their assessment of
medium weight chitosan. This ﬁnding proved that the molecular weight
of chitosan played a more remarkable inﬂuence on their gelling prop-
erties than the degree of deacetylation of chitosan used in preparing the
in situ gelling formulations.
3.2. Rheological studies of gelation
This study was carried out to understand the structural and dynamic
features of chitosan/ß-glycerophosphate formulations. During rheolo-
gical analysis, samples were directly in contact with the heated rhe-
ometer plate at the temperature of interest, which simulated the
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physiological conditions of the bladder. A strain of 1% and frequency of
1 Hz were selected for the current rheological study so that the storage
modulus (G′) and loss modulus (G″) of the samples were independent of
the applied strain.
Frequency dependent rheological proﬁles of 1% w/v pure chitosan
solutions are characteristic of viscous liquids, where G′ is lower than G″
at a particular frequency. This behaviour was evident with all studied
chitosan samples (LCHI, MCHI and HCHI) as G″ remained greater than
G′ at 25 and 37 °C during frequency sweep analysis, inferring the ab-
sence of gelation (data not shown). This data is in good agreement with
the report by Supper et al (2013), where G′ was lower than G″ during
frequency sweep studies carried out with 1.5% w/v chitosan solutions
at 20, 30 and 40 °C.
Gels typically display solid-like mechanical proﬁles, where the
storage modulus (G′) is greater than the loss modulus (G″) throughout
the evaluated frequency ranges. LCHIGP, MCHIGP and HCHIGP dis-
played gel-like behaviour at the onset of all rheological analysis (Fig. 2).
This behaviour is desirable as it supports the rapid gelation of the
samples at physiological temperature. Moreover, drug incorporation
into the CHIGP formulations as well as urine presence in the bladder
will potentially increase their gelation temperature and time.
With frequency sweep analysis at 37 °C, the greater the similarity in
the values of G′ and G″, the weaker the gel. On the other hand, stronger
gels exhibit rheological proﬁles, where the elastic modulus (G′) is
greater than the viscous modulus (G″) (Ström et al., 2014). HCHI based
formulations displayed superior gel strength (in terms of their G′/G″
values at frequency of 0.1 Hz during frequency sweep at 37 °C) relative
to MCHI and LCHI based samples (Table 1). There was statistically
signiﬁcant diﬀerence between the gel strength of LCHIGP and MCHIGP
as well as between LCHIGP and HCHIGP (p < 0.05), but the gel
strength of MCHIGP and HCHIGP was similar (p > 0.05). This ﬁnding
indicated that both MCHIGP and HCHIGP formulations may be poten-
tially less susceptible to rapid erosion by urine in the bladder.
The temperature ramp analysis was conducted from 20 to 50 °C
because this range was suﬃcient to study the transition of the drug
carrier from the sol (≤25 °C) to the gel state (25–37 °C). Formulations
intended for intravesical delivery ideally should have a gelation tem-
perature of 30–36 °C (Choi et al., 1998). This ensures that such drug
carriers remain liquid at room temperature during injection through the
catheter and only transform into a gel within the bladder. In situ gelling
systems with gelation temperature above 37 °C are not suitable for in-
travesical administration as they could be readily washed out of the
bladder during urine voiding since they will remain liquid at physio-
logical temperature.
For predominantly viscous materials, G″ is initially lower than G′
during temperature ramp test but as temperature increases, G″ in-
creases at a faster rate than G′ and the sol-gel transition temperature is
attained at the point of G″ and G′ intersection (Lin, 2002). Alter-
natively, gelation temperature is identiﬁed as the temperature, where
there was a greater growth rate of G′ (elastic property) relative to the G″
(viscous property) without samples necessarily displaying a cross-over
of G′ and G″ (Kim et al., 2010). This method of evaluating gelation
temperatures may be explored for CHIGP formulations with medium
viscosity showing a rheological proﬁle with storage modulus G′ greater
than the loss modulus G″ at the onset of the “temperature ramp” test
with no possibility of G′ and G″ intersection at any studied temperature
(Fig. 2). Moreover, some researchers have acknowledged that G′/G″
cross-over point during temperature ramp test may not depict the actual
gelation temperature of the material (Aliaghaie et al., 2012; Madbouly
and Ougizawa, 2006).
Our current study revealed that the temperature ramp proﬁles of
some formulations may imply that they have similar gelation tem-
peratures, which may not necessarily correlate with their ease of ge-
lation using a diﬀerent method of evaluating their thermogelation such
as vial inversion studies at 37 °C. The gelation temperatures of LCHIGP,
MCHIGP and HCHIGP formulations determined by rheological studies
Fig. 1. Exemplar images of chitosan/ß-glycerophosphate formulations at (a) room temperature and (b) 37 °C.
Table 1
Rheological properties of CHI/ß-glycerophosphate samples.
Samples pH Frequency sweep,
37 °C
Temperature ramp (20–50 °C, 1 °C/min) Time sweep for 30min at 37 °C (Pa)
G′/G″ ratio at 0.1 Hz Gelation temp
(oC)
G′ at 37 °C (Pa) tanδ at 37 °C Gelation time
(min)
G′ after 30min at 37 °C
(Pa)
tanδ after 30min at
37 °C
LCHIGP 7.4 ± 0.2 12.9 ± 1.8 30.4 ± 0.3 38.5 ± 3.5 0.04 ± 0.01 1.6 ± 0.3 30.2 ± 0.3 0.03 ± 0.01
MCHIGP 7.5 ± 0.2 15.8 ± 0.1 29.8 ± 0.2 41.1 ± 2.2 0.03 ± 0.01 1.4 ± 0.3 59.7 ± 7.1 0.02 ± 0.03
HCHIGP 7.3 ± 0.2 16.7 ± 0.2 29.6 ± 0.1 95.8 ± 5.5 0.03 ± 0.01 1.0 ± 0.1 138.0 ± 7.9 0.02 ± 0.02
*Greater G′/G″ values at 0.1 Hz (frequency sweep at 37 °C) infer stronger gels; storage modulus (G′) values at 37 °C during temperature ramp test as well as G′ after
30min during time sweep test depict elastic property and correlate with their ease of gelation. Loss factor or tanδ was calculated as tanG″/G′ ratio; when these values
closest to zero this indicates greater ease of gelation (n=3).
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were 30.4 ± 0.3 °C, 29.8 ± 0.2 °C, and 29.6 ± 0.1 °C, respectively
(p > 0.05). LCHIGP, MCHIGP and HCHIGP displayed similar gelation
temperature based on the temperature at which there was a rapid
change in their tanδ values (Fig. S8, Supplementary Information). So,
there was the need to deﬁne the elastic potential of our CHIGP for-
mulations based on their G′ and tanδ values at physiological tempera-
ture of 37 °C (Table 1). HCHIGP displayed signiﬁcant greater extent of
elastic features (95.8 ± 5.5 Pa) relative to MCHIGP (41.1 ± 2.2 Pa)
and LCHIGP (38.5 ± 3.5 Pa) (p < 0.05). Similarly, tanδ values of
MCHIGP and HCHIGP were smaller than that of LCHIGP, inferring that
chitosan molecular weight has substantial eﬀect on the ease of gelation
of CHIGP in situ gelling systems despite the fact that MCHIGP and
HCHIGP displayed similar tanδ values during temperature ramp and
time sweep test.
Based on rheological time sweep at 37 °C for 30min (Fig. 2b), the
gelation times of LCHIGP, MCHIGP and HCHIGP were found to be
1.6 ± 0.3, 1.4 ± 0.3 and 1.0 ± 0.1min, respectively, with HCHIGP
forming gel most readily. As there was no signiﬁcant diﬀerences in their
gelation time based on their sharp increase in G′ relative to G″ as well as
their tanδ values at any particular time, G′ values of the gels as well as
their tanδ values were determined after maintaining the samples at
37 °C for 30min. HCHIGP displayed a 2.3-fold and 4.3-fold increase in
elastic features, relative to MCHIGP and LCHIGP, respectively. This
result indicated that chitosan molecular weight inﬂuenced the gelation
potential and gel strength of the formulations with β-glycerophosphate.
This ﬁnding is in good agreement with vial inversion data for MCHIGP
and HCHIGP formulations. In contrast, the results observed for LCHIGP
diﬀers as it formed gel less readily and the gel reversed to its sol state
upon prolonged incubation at 37 °C (Fig. 1), whereas temperature ramp
and time sweep studies indicated that it displayed similar gelation
temperature and time with that of MCHIGP and HCHIGP formulations.
Nevertheless, gel strength evaluation conﬁrmed that LCHIGP was the
weakest gel. We conclude that the elastic modulus (G′) measured at
37 °C may be a useful parameter for evaluating the gelation potential of
CHIGP formulations, in addition to the already established techniques
used in rheology to determine gelation temperature and time: (1) G′/G″
intersection evaluated during temperature ramp and time sweep test;
(2) temperature and time where there is a rapid increase in G′ relative
to G″.
It should be noted that all these rheological experiments were per-
formed with the samples that were not diluted with urine. Following
the intravesical administration of these in situ gelling formulations a
dilution with urine is expected. This could potentially aﬀect the gela-
tion time. The eﬀect of dilution of these formulations with urine was
evaluated in a later section, describing retention on the bladder mu-
cosa.
3.3. Syringeability through the urethral catheter
Syringeability is a critical parameter for evaluating the eﬃciency of
intravesical dosage forms. A formulation that could ﬂow through the
catheter readily to quickly reach the bladder is one of the desirable
attributes for intravesical delivery. Since administration of intravesical
formulations is usually carried out at an ambient temperature, the
syringeability test of our samples was conducted using a texture ana-
lyser at 25 °C.
Fig. 3 shows the values of work required to release chitosan and
CHIGP formulations from the syringe through a catheter, which is in-
versely proportional to syringeability of these formulations. The values
for the work of compression of 0.9% NaCl, LCHI, MCHI, HCHI, LCHIGP,
MCHIGP, HCHIGP were 3.75 ± 0.62 N·mm, 11.60 ± 0.94 N·mm,
18.07 ± 2.80 N·mm, 20.54 ± 1.63 N·mm, 16.29 ± 2.24 N·mm,
24.62 ± 2.05 N·mm, and 26.03 ± 1.38 N·mm, respectively. Sodium
chloride (0.9% w/v), which is typically used to dissolve mitomycin-C
for intravesical applications, displayed the lowest work of compression
amongst all studied samples, implying that it was the most syringeable.
There was statistically signiﬁcant diﬀerence between the work of
compression of 0.9% sodium chloride solution and all the other studied
samples (p < 0.05). Chitosan molecular weight had a strong inﬂuence
on the syringeability of the samples as LCHI with or without β-
Fig. 2. Exemplar rheological proﬁles of LCHIGP (red), MCHIGP (green) and HCHIGP (blue) showing (a) the temperature-dependent changes in viscoelastic properties
at ramp rate 1 °C/min; (b) time-dependent viscoelastic changes of samples maintained at 37 °C for 30min. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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glycerophosphate were more syringeable than MCHI, MCHIGP, HCHI
and HCHIGP (p < 0.05). However, blank and β-glycerophosphate
containing MCHI and HCHI samples displayed similar work of com-
pression (p > 0.05). This may be related to a gradual growth in chit-
osan molecular weight of 62 kDa, 124 kDa and 370 kDa for LCHI, MCHI
and HCHI, respectively, as greater molecular weight of macromolecules
results in higher solution viscosity and better resistance to ﬂow. Also,
the decreased syringeability may become less remarkable with further
increase in chitosan molecular weight evident with MCHI and HCHI
based samples. It should be noted that all values of the work of com-
pression determined for the CHI and CHIGP systems (14–26 N·mm)
were lower than the syringeability of chitosan and poloxamer gel based
formulations reported in the study of Senyiğit et al (30–130 N·mm),
indicating that our formulations are also syringeable.
3.4. Retention study on bladder tissue
The ability of polymeric dispersions to ﬂow and adhere onto mu-
cosal membranes is dependent on the surface energy between the drug
carrier and mucosal surface. In situ gelling systems possess lower sur-
face energy than that of the mucosal surfaces and readily spread over
them, thereby maximising the contact area and optimising adhesion
(Smart, 2005). Thus such systems are desirable to promote urothelial
mucoadhesion and resistance to urine wash-out.
Ex vivo porcine urinary bladder retention studies were performed
with ﬂuorescein sodium as a model compound formulated using both
chitosan solutions and their mixtures with ß-glycerophosphate. FITC-
dextran (3–5 kDa) was also used in these experiments as a negative
control due to well-known poor adhesiveness of this oligomeric poly-
saccharide to mucosal tissues (Štorha et al., 2013). WO50 is deﬁned as
the volume of biologically relevant ﬂuid (simulated urine) required to
wash out 50% of the ﬂuorescent formulation from mucosal surface
(Mun et al., 2016). Fig. 4 presents the results of these wash oﬀ ex-
periments in the form of ﬂuorescent images. The relative ﬂuorescence
intensity values were used to calculate the wash out50 values (WO50) of
the formulations. It is clearly seen that FITC-dextran was removed from
the surface of bladder mucosa with the ﬁrst 10mL of simulated urine,
which is consistent with our previous reports (Kaldybekov et al., 2018;
Kolawole et al., 2018; Mun et al., 2016). Formulations composed of
chitosans and ﬂuorescein sodium demonstrated excellent retention
performance on the bladder surface with HCHI displaying superior re-
sistance to urine wash out compared to its lower molecular weight
analogues (p < 0.05). The formulations containing ß-glyceropho-
sphate displayed reduced mucoadhesive properties relative to their
respective chitosan solutions. For example, WO50 value for HCHI
(14mL) was signiﬁcantly higher compared to its HCHIGP formulation
(9mL). This was a surprising result as one would expected the combi-
nation of excellent mucoadhesive properties of chitosan with formation
of a gel in situ would provide a synergistic or enhanced retention eﬀects
on mucosa (Zahir-Jouzdani et al., 2018). However, this is not the case.
There was no signiﬁcant diﬀerence between the ﬂuorescence re-
tention proﬁles of FITC-dextran and FS/LCHI, FS/LCHIGP, FS/MCHIGP
and FS/HCHIGP after washing with 10mL of artiﬁcial urine
(p > 0.05), but the mucoadhesiveness of FS/MCHI and FS/HCHI was
greater than that of FITC-dextran depicted by ﬂuorescence intensity
(Fig. 4a & b) (p < 0.05). With 20mL artiﬁcial urine washing, the
ﬂuorescence retention of FS/HCHIGP was greater than that of FITC-
dextran (p < 0.05). The signiﬁcant diﬀerence between the mu-
coadhesiveness of FITC-dextran and MCHIGP was evident after 4
washing cycles with 40mL artiﬁcial urine (p < 0.05). The mu-
coadhesive properties of FS/LCHI and FS/LCHIGP were similar to that
of FITC-dextran after washing with 50mL artiﬁcial urine (Fig. 4a & b).
Furthermore, FS/LCHI, FS/LCHIGP and FS/MCHIGP displayed si-
milar WO50 values with FITC-dextran (p > 0.05). On the other hand,
FS/MCHI, FS/HCHI and FS/HCHIGP were more mucoadhesive than
FITC-dextran based on their WO50 values (Fig. 5). This ﬁnding de-
monstrated that high molecular weight chitosan is the most eﬃcient
grade to formulate CHIGP delivery systems for intravesical adminis-
tration.
3.5. Mucoadhesive properties tested using tensile method
The tensile method was used to probe the mucoadhesive properties
of the formulations further (Khutoryanskiy, 2011). In these experiments
0.4 mL of each liquid formulation was placed between two diﬀerent
bladder mucosal surfaces and, after holding these tissues in contact for
120 s, they were withdrawn from each other, recording the force versus
distance proﬁles. The maximal force of detachment determined in these
experiments indicated the force needed to surmount the adhesive bonds
between the formulations and the bladder mucosa, while the area under
the force-distance curves gave the total work of adhesion (Boateng
et al., 2013; Caló et al., 2016). Typical detachment proﬁle is presented
in Fig. S6 (Supplementary information). As it was expected, dextran as
the non-mucoadhesive control displayed the lowest force of detachment
and total work of adhesion values (Fig. 6). Pure chitosan samples had a
greater mucoadhesive performance compared to CHIGP formulations.
For example, the values of maximal detachment force and total work of
adhesion determined for HCHI (0.41 ± 0.02 N and
0.56 ± 0.13 N·mm, respectively) were signiﬁcantly greater (p < 0.05)
than the values for HCHIGP (0.13 ± 0.01 N and 0.35 ± 0.02 N·mm,
respectively).
The detachment characteristics of all formulations correlate well
with their resistance to urine wash-out: the use of both methods in-
dicates greater mucoadhesiveness of chitosan samples compared to
their mixtures with ß-glycerophosphate.
To get a further insight into the reasons why chitosan solutions
alone show superior retention and mucoadhesive properties compared
to the formulations of chitosan with ß-glycerophosphate, additional
experiments were performed by determining zeta potential of all sam-
ples at 25 °C and 37 °C (Table 2). The chitosan formulations displayed a
relatively high positive values of zeta potential (ZP) due to the cationic
nature of chitosan associated with the presence of free amino groups.
For the formulations with β-glycerophosphate, ZP values signiﬁcantly
decreased compared to CHI (p < 0.05). This trend was observed both
Fig. 3. Syringeability of chitosan and chitosan/ß-glycerophosphate formula-
tions evaluated as the work done to expel samples from 2mL plastic syringes
into the urethral catheter. Experiment was conducted at 25 °C using the Texture
Analyser (Stable Micro Systems Ltd, UK), n= 3. Syringeability is inversely
proportional to the work of compression; there was signiﬁcant statistical dif-
ference in the work of compression values between all groups of samples
(p < 0.05) except those designated with “ns”. 0.9% sodium chloride solution
served as the control.
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at 25 °C and 37 °C. A signiﬁcant reduction in ZP values is related to
partial neutralisation of cationic chitosan macromolecules with anionic
β-glycerophosphate, which is in good agreement with the literature
data (Owczarz et al., 2018).
It is well established that excellent mucoadhesive properties of
chitosan are related to the interactions of its macromolecules with ne-
gatively charged mucin. The nature of these interactions is pre-
dominantly electrostatic; however, the contribution of hydrogen
bonding and hydrophobic eﬀects cannot be completely disregarded
(Sogias et al., 2008). A reduction in the positive values of zeta potential
observed in the case of CHIGP formulations compared to chitosan alone
may well be the main reason for their decreased interactions with
bladder mucosal surfaces. Second factor that could possibly contribute
to weakening of mucoadhesive performance is the physical cross-
linking of chitosan macromolecules caused by their interactions with β-
glycerophosphate. This cross-linking could restrict diﬀusion of chitosan
macromolecules and prevent them from formation of an inter-
penetrating layer with mucins present on mucosal surface. According to
the diﬀusion theory of mucoadhesion, this could reduce the mu-
coadhesive properties of the formulations (Khutoryanskiy, 2011).
3.6. Mitomycin-C in vitro release
Dialysis technique using semi-permeable membrane is an
Fig. 4. Retention study of ﬂuorescein sodium (FS) formulations and FITC-dextran as a negative control. (a) Exemplar microphotographs showing wash-out from
porcine urinary bladder tissue with artiﬁcial urine solution over 5 washing cycles, scale bar is 2mm; (b). Mucosal retention on porcine urinary bladder tissue. Result
presented as mean ± standard deviation, n= 3, * depicts statistically signiﬁcant diﬀerences between samples (p < 0.05).
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established method for drug release studies in intravesical drug delivery
(Senyiğit et al., 2015; GuhaSarkar et al., 2017). Mitomycin-C (MMC)
was chosen in the current study as a drug that is typically used in-
travesically to treat superﬁcial/non-invasive bladder cancer. Fig. 7
shows the release proﬁles from drug solution, CHI, and CHIGP for-
mulations.
Within the ﬁrst 30min, the release of mitomycin-C from the free
drug solution, LCHI, MCHI, HCHI, LCHIGP, MCHIGP and HCHIGP
samples was 52 ± 21, 14 ± 2, 11 ± 2, 8 ± 1, 18 ± 2, 14 ± 1 and
11 ± 1%, respectively. Expectedly, drug release from free mitomycin-
C solution was the greatest after 30min, which was more signiﬁcant
than that of CHI and CHIGP formulations (p < 0.05). After 6 h, the
drug release proﬁle for free mitomycin-C solution was 100% and it was
statistically similar to that of LCHIGP (p > 0.05), inferring that in situ
gelling systems based on low molecular weight chitosan had the least
ability to sustain drug release amongst the CHIGP samples. As expected,
the release from the free drug solution was faster compared to polymer-
containing formulations, which is consistent with the literature on re-
lease studies involving small molecules (see Zhou et al., 2008 as an
example). There was no signiﬁcant diﬀerence in the drug release pat-
tern of the pure chitosan formulations (LCHI, MCHI and HCHI), as
compared at 0.5 h and 6 h (p > 0.05). This behaviour is not ideal for
intravesical dosage forms, where it is desirable for a substantial amount
of the therapeutic dose to be available after transurethral resection of
the tumours, for superﬁcial bladder cancer management. In contrast,
there was some inﬂuence of chitosan molecular weight on the drug
release from CHIGP samples. For example, a cumulative release of
63 ± 23%, 39 ± 20% and 37 ± 17% of the drug was observed over
6 h release period for LCHIGP, MCHIGP, and HCHIGP samples, re-
spectively. This ﬁnding is in good agreement with the report by Zhou
et al. (2008), where high molecular weight chitosan based gels (CHI-
αβ-GP) exhibited slower adriamycin release compared to lower mole-
cular weight polysaccharide based formulations (50% vs 70%) over
24 h. There was statistically signiﬁcant diﬀerence in the cumulative
amount of drug released from MCHIGP and HCHIGP compared to the
free drug solution (p < 0.05). The drug release behaviour of the
Fig. 5. Artiﬁcial urine wash out-50 (WO50) values determined for diﬀerent
formulations. Results presented as mean ± standard deviation, n= 3, * de-
picts statistically signiﬁcant diﬀerences between samples (p < 0.05).
Fig. 6. Adhesion of CHI (1% w/v) and CHIGP samples to porcine bladder mucosa using tensile method: (a) force of detachment values; (b) work of adhesion values.
Results presented as mean ± standard deviation, n=3, Asterisk (*) implies statistically signiﬁcant diﬀerence between data sets (p < 0.05).
Table 2
Zeta potential values of chitosan solutions (CHI) and chitosan/ß-glyceropho-
sphate mixtures (CHIGP) at 25 °C and 37 °C.
Chitosan Samples Zeta potential, 25 °C (mV) Zeta potential, 37 °C (mV)
CHI CHIGP CHI CHIGP
Low 43.9 ± 2.7 1.5 ± 0.1 46.0 ± 1.6 1.1 ± 0.2
Medium 50.1 ± 7.8 1.9 ± 0.1 50.0 ± 2.7 1.2 ± 0.2
High 56.6 ± 2.3 2.3 ± 0.1 51.8 ± 0.3 1.6 ± 0.2
Fig. 7. In vitro release proﬁles of mitomycin-C from free drug solution, chitosan
solutions and CHIGP formulations in pH 6.2 artiﬁcial urine. Results are pre-
sented as mean values (n=3); error bars are not shown to avoid overlapping
for some samples.
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samples beyond 6 h was not studied because mitomycin-C degraded
with prolonged exposure to artiﬁcial urine (Myers et al., 2017). The
drug degradation is due to the hydrolysis of its labile ester bond in the
aqueous medium. Nevertheless, drug degradation in the physiological
ﬂuid may be avoided as its release and diﬀusion across underlying
diseased tissues will take place quickly.
LCHIGP/MMC displayed 1.6-fold and 1.7-fold increase in the
amount of mitomycin-C released after 6 h release period, inferring that
LCHIGP favoured an overall rapid drug release relative to MCHIGP and
HCHIGP. The amount of MMC released from chitosan decorated poly-Ɛ-
caprolactone nanoparticles evaluated by Bilensoy et al. (2009) was 80%
in 6 h release period using phosphate buﬀer (pH 6.0). In a subsequent
report, in vitro studies were carried out by the same group using a
diﬀerent release medium of citrate buﬀer but having similar pH 6.0
(Erdoğar et al., 2012), and 89%, 92% and 91% of MMC were respec-
tively released in 15min from chitosan, poly-L-lysine-coated and chit-
osan coated poly-Ɛ-caprolactone nanoparticles, inferring that the type
of release medium used modulates the drug release proﬁle rather than
their pH values. Moreover, the use of physiologically relevant release
medium like simulated urine used in the current study is valuable to
generate reliable drug release data. These drug carriers exhibited fast
drug release, which will necessitate frequent dosing that is not con-
venient for bladder cancer patients as their therapy is carried out in the
hospital. In contrast, our MCHIGP/MMC and HCHIGP/MMC favoured
sustained drug release as 39 ± 20 and 37 ± 1% of the drug were
respectively released in 6 h from these formulations. This may prolong
dosing interval and minimise bladder cancer recurrence. On the other
hand, LCHIGP/MMC, with 63 ± 23% of drug released within 6 h,
displayed a comparable proﬁle with the best chitosan based formula-
tions (chitosan coated PCL nanoparticles) reported by Bilensoy et al
(2009).
4. Conclusions
In situ gelling systems composed of chitosan of three molecular
weights and β-glycerophosphate were formulated in this work and
studies for their potential applicability for intravesical delivery of mi-
tomycin-C to treat bladder cancer were carried out. These formulations
were evaluated for their ability to form gels in situ, rheological prop-
erties, syringeability, retention on and adhesion to the urinary bladder
mucosa as well as the drug release in vitro.
The molecular weight of chitosan was found to modulate syringe-
ability, gelation, mucoadhesive properties and drug release proﬁles of
the formulations. Chitosan with the highest molecular weight (370 kDa)
combined with β-glycerophosphate displayed superior resistance to
urine wash-out compared to the formulations with lower molecular
weights; it also provided controlled release of mitomycin-C over 6 h
period.
This work showed that the mucoadhesive properties of chitosan are
reduced by its formulation with β-glycerophosphate. This is related to
the reduction in positive values of zeta potential for these formulations
compared to chitosan alone. So, in terms of the retention of the for-
mulations in the bladder, the use of in situ gelling dosage forms com-
posed of chitosan and β-glycerophosphate did not show any superior
mucoadhesive beneﬁt over simple solutions of chitosan without gela-
tion properties. However, the drug release pattern from chitosan solu-
tions demonstrated that the local availability of mitomycin-C in the
bladder may be limited as a maximum of 15.1–24.9% of the drug was
released over the study period. Thus, HCHIGP still demonstrated su-
perior urothelial mucoadhesive properties relative to LCHIGP and
MCHIGP. Future work will explore chemical modiﬁcation of chitosan
prior to formulating with β-glycerophosphate to develop in situ gelling
systems with improved mucoadhesiveness.
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